ID Source | ID |
---|---|
PubMed CID | 149015 |
CHEMBL ID | 1234672 |
SCHEMBL ID | 9590644 |
MeSH ID | M0068415 |
Synonym |
---|
5'-uridylic acid, 2'-deoxy-5-nitro- |
unii-m5xxz2mq75 |
m5xxz2mq75 , |
63689-79-2 |
5-nitro-2'-deoxyuridine 5'-monophosphate |
CHEMBL1234672 , |
NDN , |
2'-deoxy-5-nitrouridine 5'-(dihydrogen phosphate) |
5-nitro-2'-deoxyuridylate |
[(2r,3s,5r)-3-hydroxy-5-(5-nitro-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate |
SCHEMBL9590644 |
bdbm50010241 |
DTXSID30213085 |
5-nitro-2'-deoxyuridylic acid |
5-nitrodeoxyuridylic acid |
Q27463760 |
Q27283526 |
PD195095 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Thymidylate synthase | Lacticaseibacillus casei | Ki | 0.0290 | 0.0100 | 1.6550 | 9.3900 | AID1134942 |
Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0290 | 0.0000 | 0.6068 | 9.2330 | AID1134942 |
Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0290 | 0.0000 | 0.3845 | 8.6000 | AID1134942 |
Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0290 | 0.0000 | 0.1868 | 3.9500 | AID1134942 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1134942 | Competitive inhibition of thymidylate synthase purified from methotrexate-resistant Lactobacillus casei using 2'-deoxy[5-3H]uridine 5'-phosphate by radioisotope assay | 1979 | Journal of medicinal chemistry, Sep, Volume: 22, Issue:9 | 5-Cyano-2'-deoxyuridine 5'-phosphate: a potent competitive inhibitor of thymidylate synthetase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (85.71) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.21) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |